For example, Pfizer recently withdrew the sickle cell disease drug Oxbryta from the market, which was the centerpiece of its ...

That's because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

That’s because FDA flexibility can mean approval for drugs that are too dangerous or simply do not work. Skorney cited a drug ...

If you've experienced serious side effects from Oxbryta, find out if you qualify for compensation. CHEYENNE, WY / ACCESSWIRE / October 23, 2024 / InjuryClaims.com is connecting people who may have ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

The study's design and endpoints have been crafted to support full approval, distinguishing it from the development path of competitor drugs like Oxbryta. The SCD market has become increasingly ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...